[A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer].

MLA

Aikawa, T., et al. “[A Controlled Study with Medroxyprogesterone Acetate (MPA) Alone or in Combination with Cyclophosphamide (CPA) in the Treatment of Advanced or Recurrent Breast Cancer Unresponsive to Other Therapies. Osaka Study Group for the Treatment of Breast Cancer].” Gan to Kagaku Ryoho. Cancer & Chemotherapy, vol. 18, no. 6, May 1991, pp. 995–1002. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=1827575&authtype=sso&custid=ns315887.

APA

Aikawa, T., Yayoi, E., Takatsuka, Y., Maeura, Y., & Miyauchi, K. (1991). [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 18(6), 995–1002.

Chicago

Aikawa, T, E Yayoi, Y Takatsuka, Y Maeura, and K Miyauchi. 1991. “[A Controlled Study with Medroxyprogesterone Acetate (MPA) Alone or in Combination with Cyclophosphamide (CPA) in the Treatment of Advanced or Recurrent Breast Cancer Unresponsive to Other Therapies. Osaka Study Group for the Treatment of Breast Cancer].” Gan to Kagaku Ryoho. Cancer & Chemotherapy 18 (6): 995–1002. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=1827575&authtype=sso&custid=ns315887.